FACTOR V LEIDEN MUTATION AND ITS IMPACT ON PREGNANCY COMPLICATIONS

Ľubica Hammerová1, Ján Chabada1, Juraj Drobný1, Angelika Bátorová2

Comenius University, Faculty of Medicine University Hospital, Bratislava, Slovakia: 1st Department of Gynaecology and Obstetrics1
The National Haemophilia Centre, Institute of Haematology and Blood Transfusion, University Hospital, Bratislava, Slovakia2

Summary: Objective: The aim of this prospective study was to find the association between the factor V Leiden mutation and adverse pregnancy outcomes. Methods: This study is an analysis of a prospective observational study of the frequency of placenta-mediated complications of factor V Leiden mutation carriers. We compared pregnancy outcomes of 11 women with a heterozygous form of the factor V Leiden mutation with 41 women of a control group. Results: All pregnancies ended with delivery of a living infant. None of the 52 pregnancies were complicated by venous thromboembolism. There were a few significant differences regarding placenta-mediated complications. The gestational age at delivery showed small significant differences. There was a significant difference in the birth weight deviation in percentage between FVL carriers and controls. The incidence of blood loss exceeding 1000 ml was higher in the control group. Conclusions: Carriership of the factor V Leiden mutation did not affect the incidence of preeclampsia. Adverse pregnancy outcomes such as placental abruption were rare. Eclampsia, intrauterine fetal death and venous thromboembolism did not occur. Our results provide evidence that the maternal heterozygous FVL mutation did not increase the risk of an adverse pregnancy outcome.

Key words: Pregnancy; Thrombophilia; Factor V Leiden; Venous thromboembolism; Adverse pregnancy outcome; Preeclampsia; IUGR, IUFD; Placental abruption

Introduction

During pregnancy the gentle haemostatic balance shifts towards enhanced coagulation, resulting in an increased risk of venous thromboembolism. Pulmonary embolism is the main cause of maternal mortality in developed countries (3). As a result of influencing placental perfusion, thrombotic processes have been described as an important pathogenetic factor in some severe obstetric conditions (such as preeclampsia, intrauterine growth restriction (IUGR) and placental abruption).

Thrombotic events have also been found in fetal circulation. Both congenital and acquired thrombophilias are implicated in pathophysiological processes associated with thrombotic damage of the placenta as well as with an increased risk of venous thromboembolism (VTE) (Tab. 1).

Activated factor V (FVa) acts as a cofactor to activated factor X (FXa) in the conversion of prothrombin. The procoagulant function of FVa is down-regulated by the serine protease activated protein C (APC) for haemostatic maintenance. The activation of protein C begins on the surface of endothelial cells through the thrombin-thrombomodulin complex.

Tab. 1: Incidence of hereditary thrombophilia in the general population and in patients with venous thromboembolism (VTE).

<table>
<thead>
<tr>
<th></th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>in the general population</td>
</tr>
<tr>
<td>Factor V Leiden (heterozygous)</td>
<td>3.60–6.00</td>
</tr>
<tr>
<td>Factor V Leiden (homozygous)</td>
<td>0.10–0.02</td>
</tr>
<tr>
<td>Protein C deficiency</td>
<td>0.14–0.50</td>
</tr>
<tr>
<td>Protein S deficiency</td>
<td>unknown</td>
</tr>
<tr>
<td>Antithrombin deficiency (type I)</td>
<td>0.02–0.17</td>
</tr>
<tr>
<td>Prothrombin G20210A mutation</td>
<td>1–4</td>
</tr>
<tr>
<td>Hyperhomocysteinemia</td>
<td>5–10</td>
</tr>
</tbody>
</table>

Information obtained from Ref. 2.

The factor V Leiden mutation is the most common thrombophilia and its prevalence of heterozygosity in Caucasian
population varies between 2–15%. The highest prevalence is in Northern Europe and in the Middle East (37).

Activated protein C resistance (APC resistance) was first described by Dahlbäck in 1993 (8). More than 95% of APC resistance cases are due to a point mutation in the factor V gene known as the Leiden mutation (9). The molecular basis of this phenotype was identified as a single point mutation G→A in position 1691, changing arginine (Arg506) of factor V to glutamine (2). In 1998, two other rare factor V mutations were found: arginine (Arg164) to glycine (FV Hong-Kong) or threonine (FV Cambridge) (5, 36). The mutated factor Va becomes resistant to proteolytic inactivation of activated protein C. The rate of inactivation of the mutant factor V is diminished, resulting in a higher plasma level of thrombin. This rising thrombin production results in a predisposition to venous thromboembolism (VTE) (29). The risk of VTE associated with the factor V mutation is amplified by other risk factors (Tab. 2).

<table>
<thead>
<tr>
<th>Age</th>
<th>Malignancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous thrombosis</td>
<td>Antiphospholipid syndrome</td>
</tr>
<tr>
<td>Immobilization</td>
<td>Myeloproliferative disorders</td>
</tr>
<tr>
<td>Surgery</td>
<td>Venous stasis</td>
</tr>
<tr>
<td>Trauma</td>
<td>Obesity</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>Sepsis</td>
</tr>
</tbody>
</table>

Tab. 2: Risk factors of deep venous thrombosis in pregnancy.

Preeclampsia, placental abruption, intrauterine growth restriction (IUGR) and intrauterine fetal death (IUFD) contribute to maternal and fetal morbidity and mortality.

Preeclampsia can be caused by poor placentation involving the spiral arteries and leads to inadequate uteroplacental flow. Between the 8th and 18th gestation week an altered trophoblast invasion of the spiral arterial walls appears. The result is a massive maternal inflammatory response (12). Placental changes characterized by superficial endovascular cytotrophoblast invasion in the spiral arteries and intervillous space are called placental vasculopathy. Placental apoptotic and necrotic debris reaches maternal circulation, resulting in endothelial damage and activation of blood coagulation (25). Some studies suggest that poor placentation provokes maternal circulation, which compensates by increasing the blood pressure (15). The risk factors of preeclampsia are described in Table 3.

Placental abruption is a serious obstetric condition associated with high perinatal mortality and high maternal morbidity and mortality. Known risk factors are shown in Table 4.

<table>
<thead>
<tr>
<th>Uterus trauma</th>
<th>Cigarette smoking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Advanced maternal age</td>
</tr>
<tr>
<td>Fetal growth restriction</td>
<td>Multiparity</td>
</tr>
</tbody>
</table>

Tab. 4: Risk factors for placental abruption.

Information obtained from Ref. 14.

Abruption of the placenta is characterized as the separation of the implanted placenta by hemorrhage into the decidua basalis. This process starts with uterine vasospasm followed by relaxation and consequently venous stasis. The arterioles rupture and separation of the placenta occur. Placental biopsies after abruption show the same abnormal vascular structures as in preeclampsia (33).

Intrauterine growth restriction (IUGR) has serious consequences for neonates. IUGR is associated with an increased risk of premature birth, increased morbidity, including necrotizing enterocolitis, hypoxic brain injury, retinopathy of prematurity, and, later in life, obesity, diabetes and ischaemic heart diseases. The placenta is the interface between fetal and maternal circulation and plays an essential role in supporting normal fetal growth. Pathology affecting the placenta is responsible for the majority of IUGR (7).

The relationship between intrauterine fetal death (IUFD) and the factor V mutation is debatable. It is unlikely that the factor V Leiden mutation can cause early miscarriage by increasing blood coagulation because fetal nutrition is, up to the 10th week of pregnancy, mainly histiotrophic, with the maternal intraplacental circulation being fully established after the third month of gestation (4). Numerous studies have been published and the results are controversial due to the between-study heterogeneity.

Material and Methods

The aim of this prospective study was to find the association between the factor V Leiden mutation and adverse pregnancy outcomes such as preeclampsia, eclampsia, intrauterine growth restriction (IUGR), intrauterine fetal death (IUFD), prematurity, placental abruption and venous thromboembolism. This study is an analysis of a prospective observational study of the frequency of placenta-mediated complications of factor V Leiden mutation carriers. Patients

Tab. 3: Risk factors of preeclampsia.

<table>
<thead>
<tr>
<th>Primipaternity</th>
<th>Chronic hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy after donor insemination</td>
<td>Renal disease</td>
</tr>
<tr>
<td>Pregnancy after oocyte/embryo donation</td>
<td>Obesity and insulin resistance</td>
</tr>
<tr>
<td>Extremes of maternal age</td>
<td>Pregestational diabetes mellitus</td>
</tr>
<tr>
<td>Multifetal gestation</td>
<td>Maternal infections</td>
</tr>
<tr>
<td>Preeclampsia in previous pregnancy</td>
<td>Hydropic degeneration of the placenta</td>
</tr>
</tbody>
</table>

Information obtained from Ref. 13.
were enrolled in this study between October 2006 and September 2009 and were followed up in our antenatal clinic. All subjects gave informed consent in accordance with the principles of the Declaration of Helsinki. Our study included 52 women. The diagnosis of the factor V Leiden mutation was confirmed in 11 women by a polymerase chain reaction (PCR). Negative results were obtained in 41 women. All women in the study population were Caucasian. In this study we had only women with a singleton pregnancy and a history of one unexplained abortion in the first trimester before thrombophilia screening. Other inclusion criteria were the absence of venous thromboembolism before pregnancy, presence of no other thrombophilic abnormalities and a negative family history for venous thromboembolism. Women with BMI > 40, hepatopathy and nephropathy were excluded. We observed these women from the 10th–15th week of pregnancy until their delivery. Five women with the factor V Leiden mutation were treated during pregnancy with a prophylactic dose of Nadroparin. The factor V Leiden carriers were compared with controls in terms of gestational age at delivery, pre-eclampsia, eclampsia, intrauterine fetal death, intrauterine growth restriction, placental abruption, blood loss at delivery, frequency of venous thromboembolism and superficial thrombophlebitis. The paired t-test was used for statistical evaluation.

**Results**

The median age at the time of enrollment of the 11 women with heterozygous factor V Leiden was 29 years (range 19–34 years). None of our women experienced venous thromboembolism before their pregnancy. The median age of the 41 controls was 28 years (range 20–34 years). None of the controls had a history of thrombosis. Data for pregnancy outcomes in patients and controls are shown in Table 5. All pregnancies ended with delivery of a living infant. None of the 52 pregnancies were complicated by venous thromboembolism. Thromboprophylaxis and compression stockings which may have prevented some VTE (five women with the factor V Leiden mutation, were treated with Nadroparin and one had compression stockings because of varicose veins of lower extremities) were provided more to the factor V Leiden mutation carriers than to the controls.

There were significant differences regarding placenta-mediated complications. The gestational age at delivery showed significant differences (p < 0.05). There was a significant difference in the birth weight deviation between FVL carriers and controls (p < 0.05). The total blood loss at delivery defined by measuring and estimating was lower in the factor V Leiden carriers, but the difference was not significant.

The incidence of blood loss exceeding 1000 ml was higher in the control group (p < 0.05). Table 6 shows the comparison of total blood loss during delivery between the factor V Leiden mutation carriers and controls.

**Discussion**

There is evidence showing that women with the factor V Leiden mutation can be at an increased risk of several severe obstetric complications.

Maternal thrombophilia together with natural haemostatic changes during pregnancy shift the gentle balance towards thrombotic changes in the placenta, resulting in inadequate fetomaternal circulation and leading to decreased placental perfusion (25). Intrauterine fetal growth restriction has been defined as a birth weight below the 5th percentile for the gestational age. A higher incidence of IUGR in our study group confirms the results of several studies showing the relationship between placental pathology and maternal thrombophilia (1, 17). The etiology of IUGR is multifactorial and thrombophilia can play an additional role.

On the other hand, several studies have found no significant difference in birth weight deviation between FVL carriers and controls, thus indicating no elevated risk for IUGR (6, 11, 18, 35). A possible association may exist between IUGR and the factor V Leiden mutation but the data obtained from various studies are not homogenous.

Miscarriage is defined as a termination of the pregnancy in the first and second trimester and stillbirth as a pregnancy loss occurring after 22nd week of pregnancy. In 1998,
Our study confirmed this suggestion. Some authors suggest that the factor V Leiden carriers have less blood during delivery compared with non-carriers (11, 13, 16, 22, 23).

It is now widely accepted that recurrent miscarriage has an association between thrombophilia and abortion/stillbirth. Several authors have suggested that the factor V Leiden mutation, is associated with placental abruption in Finnish women. Placenta 2004; 25:730–734.

In our study, the prevalence of preeclampsia was not higher in FVL carriers than in controls and was in accordance with the five largest case-control studies and three prospective studies (6, 10, 11, 14, 16, 19, 20, 32).

Current evidence shows that there are similar vasculopathic changes in preeclampsia, IUGR, fetal loss and placental abruption. The etiology of placental abruption is still unclear. It is characterized by an abnormal vascular response to placental associated with increased systematic vascular resistance, enhanced platelet aggregation, activation of the coagulation system and endothelial cell dysfunction (28). Clinically, preeclampsia was defined as blood pressure higher than 160/110 mmHg, urinary protein excretion greater than 5 g/24 h and a platelet count of less than 100 000/mm³. Some studies have shown an association between thrombophilia and an early onset of severe preeclampsia but not mild or term preeclampsia. According to these studies preeclampsia is significantly associated with the factor V Leiden mutation. There is also an increased tendency for maternal complications such as disseminated intravascular coagulation (DIC) and acute renal failure (26).

In our study, the prevalence of preeclampsia was not higher in FVL carriers than in controls and was in accordance with the five largest case-control studies and three prospective studies (6, 10, 11, 14, 16, 19, 20, 32).

Some authors suggest that the factor V Leiden carriers have less blood during delivery compared with non-carriers (16). Our study confirmed this suggestion.

Conclusions

Carriership of the factor V Leiden mutation in our study did not affect the incidence of preeclampsia. Adverse pregnancy outcomes such as placental abruption were rare. Eclampsia, intrauterine fetal death and venous thromboembolism did not occur. Thromboprophylaxis may have influenced the prevalence of VTE. The incidence of blood loss during delivery exceeding 1000 ml was significantly higher in the control group. However, our small study confirmed some results of the largest studies. In patients with negative personal or family histories for thromboembolism, the heterozygous factor V Leiden mutation is associated with a lower risk of thromboembolism in pregnancy. Therefore, neither the screening of all pregnant women nor the treatment of the low risk carriers is recommended. In cases with a thrombophilic etiology close collaboration between obstetricians and haematologists is the main key to ensuring a successful pregnancy.

Acknowledgements

The authors would like to thank The National Haemophilia Centre at the Institute of Haematology and Blood Transfusion, University Hospital, Bratislava, Slovakia.

References


Received: 08/04/2010
Accepted in revised form: 23/06/2011

Corresponding author:

Ľubica Hammerová, MD, 1st Department of Gynaecology and Obstetrics, Faculty of Medicine, Comenius University, Antolská 11, 851 07 Bratislava, Slovakia; e-mail: hammerova@gmail.com